IE 11 is not supported. For an optimal experience visit our site on another browser.

Integra LifeSciences to Present at Piper Jaffray's Healthcare and the J.P. Morgan Small and Mid Cap Conferences

PLAINSBORO, N.J., Nov. 19, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at two upcoming conferences.
/ Source: GlobeNewswire

PLAINSBORO, N.J., Nov. 19, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at two upcoming conferences.

Mr. John B. Henneman, III, Executive Vice President and Chief Financial Officer of Integra, will present at the following two conferences in New York City:

  • Tuesday, November 30, 2010 at 3:00 PM ET at Piper Jaffray's 22nd Annual Healthcare Conference at The New York Palace Hotel;
  • and Thursday, December 2, 2010 at 12:45 PM ET at the J.P. Morgan Small and Mid Cap Conference 2010 at the J.P. Morgan Conference Center.

There will be no webcast for the above conferences.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT: Integra LifeSciences Holdings Corporation John B. Henneman, III, Executive Vice President, Finance and Administration and Chief Financial Officer (609) 275-0500 jack.henneman@integralife.com Investor Relations: Angela Steinway (609) 936-2268 angela.steinway@integralife.com